Valneva Shares Drop 2% and Approach Key Support at €2.26
Midday sees the Lyon-based biotech extending its downturn, as the SBF 120 also trends negatively. The stock is sinking into a technically fragile zone, below all its moving averages, and continues to be weighed down by a deteriorated annual trajectory.
Valneva Stock Dips Close to Critical Support Level
Valneva shares decline by 1.96% to €2.30 at mid-session, within an SBF 120 that is down by 0.43%. The stock is now less than 2% above its support level at €2.26, which was previously tested at the end of May and during last week's sessions.
The stock is trading below its 20-day moving average (MM20) at €2.52, showing a deviation of -8.81%, below its 50-day moving average (MM50) at €2.54, and significantly under its 200-day moving average (MM200) at €3.74, over 38% below the latter. The RSI at 40 indicates a persistent selling trend, though it has not yet reached the oversold zone.
Over the week, the stock has lost 12% and has seen a nearly 50% decline over three months, indicating a consistently deteriorating trend.
Stock Trajectory Continues to Be Hampered by Reorganization and Lowered Guidance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Today's movement follows a pattern that began in mid-May. On May 13, during the announcement of the first quarter 2026 results, the company reported a 37% decrease in revenue and a net loss of €32.1 million, along with a reorganization plan aimed at reducing operational expenses by 25 to 35% and global workforce by 10 to 15%.
On this occasion, the company also adjusted its 2026 revenue forecast to between €135 and €150 million. Factors cited during this announcement included decreased sales of third-party products and unfavorable trends in travel vaccine adoption.
The €2.26 support level remains the most closely watched technical threshold in the short term. A break below this level would open an area without recent reference points; maintaining it could preserve the possibility of stabilization after a nearly 50% drop since the start of the quarter.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.